The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was strongly positive. We sought to assess the benefit-risk balance of nab-paclitaxel plus gemcitabine using the data of the MPACT trial, as it is an...
Uložené v:
| Vydané v: | Pancreas Ročník 48; číslo 2; s. 275 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.02.2019
|
| ISSN: | 1536-4828, 1536-4828 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was strongly positive. We sought to assess the benefit-risk balance of nab-paclitaxel plus gemcitabine using the data of the MPACT trial, as it is an alternative to 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin.
This statistical method allows for the simultaneous analysis of several prioritized outcomes. The first priority outcome was survival time (overall survival). The second priority outcome was toxicity. The overall treatment effect was quantified using the overall net benefit. Multiple sensitivity analyses were performed to assess the consistency of the results according to possible patients' preferences.
In this trial, 861 patients received nab-paclitaxel plus gemcitabine or gemcitabine alone. The overall net benefit favored strongly and significantly the combination group. When only large survival differences were considered clinically relevant, the net benefit was not in favor of the combination group.
The overall net benefit is a clinically intuitive way of comparing patients with respect to all important efficacy and toxicity outcomes. The nab-paclitaxel plus gemcitabine combination has a positive benefit-risk balance, but it might not be suitable for patients who would consider losing several months of survival to avoid a significant toxic event. |
|---|---|
| AbstractList | The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was strongly positive. We sought to assess the benefit-risk balance of nab-paclitaxel plus gemcitabine using the data of the MPACT trial, as it is an alternative to 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin.OBJECTIVESThe benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was strongly positive. We sought to assess the benefit-risk balance of nab-paclitaxel plus gemcitabine using the data of the MPACT trial, as it is an alternative to 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin.This statistical method allows for the simultaneous analysis of several prioritized outcomes. The first priority outcome was survival time (overall survival). The second priority outcome was toxicity. The overall treatment effect was quantified using the overall net benefit. Multiple sensitivity analyses were performed to assess the consistency of the results according to possible patients' preferences.METHODSThis statistical method allows for the simultaneous analysis of several prioritized outcomes. The first priority outcome was survival time (overall survival). The second priority outcome was toxicity. The overall treatment effect was quantified using the overall net benefit. Multiple sensitivity analyses were performed to assess the consistency of the results according to possible patients' preferences.In this trial, 861 patients received nab-paclitaxel plus gemcitabine or gemcitabine alone. The overall net benefit favored strongly and significantly the combination group. When only large survival differences were considered clinically relevant, the net benefit was not in favor of the combination group.RESULTSIn this trial, 861 patients received nab-paclitaxel plus gemcitabine or gemcitabine alone. The overall net benefit favored strongly and significantly the combination group. When only large survival differences were considered clinically relevant, the net benefit was not in favor of the combination group.The overall net benefit is a clinically intuitive way of comparing patients with respect to all important efficacy and toxicity outcomes. The nab-paclitaxel plus gemcitabine combination has a positive benefit-risk balance, but it might not be suitable for patients who would consider losing several months of survival to avoid a significant toxic event.CONCLUSIONSThe overall net benefit is a clinically intuitive way of comparing patients with respect to all important efficacy and toxicity outcomes. The nab-paclitaxel plus gemcitabine combination has a positive benefit-risk balance, but it might not be suitable for patients who would consider losing several months of survival to avoid a significant toxic event. The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was strongly positive. We sought to assess the benefit-risk balance of nab-paclitaxel plus gemcitabine using the data of the MPACT trial, as it is an alternative to 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin. This statistical method allows for the simultaneous analysis of several prioritized outcomes. The first priority outcome was survival time (overall survival). The second priority outcome was toxicity. The overall treatment effect was quantified using the overall net benefit. Multiple sensitivity analyses were performed to assess the consistency of the results according to possible patients' preferences. In this trial, 861 patients received nab-paclitaxel plus gemcitabine or gemcitabine alone. The overall net benefit favored strongly and significantly the combination group. When only large survival differences were considered clinically relevant, the net benefit was not in favor of the combination group. The overall net benefit is a clinically intuitive way of comparing patients with respect to all important efficacy and toxicity outcomes. The nab-paclitaxel plus gemcitabine combination has a positive benefit-risk balance, but it might not be suitable for patients who would consider losing several months of survival to avoid a significant toxic event. |
| Author | Maucort-Boulch, Delphine Buyse, Marc Péron, Julien Giai, Joris |
| Author_xml | – sequence: 1 givenname: Julien surname: Péron fullname: Péron, Julien – sequence: 2 givenname: Joris surname: Giai fullname: Giai, Joris – sequence: 3 givenname: Delphine surname: Maucort-Boulch fullname: Maucort-Boulch, Delphine – sequence: 4 givenname: Marc surname: Buyse fullname: Buyse, Marc organization: International Drug Development Institute, San Francisco, CA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30629024$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URB_wDxDykUuK7ThxfCwVL6mFqirnaGtvhCFxSuxK8O-JoEidw84cPq1GMyYD33ok5JKzKWda3SxXsyk7EhepPCEjnqV5IgtRDI7ykIxDeO8ZlWb6jAxTlgvNhByR9eYN6S16rFxM1i580FuowRukbUWfYZuswNQuwhfW1Hm6xAghQnSGrnqqw984s-hbA51xvm3gnJxWUAe8OPiEvN7fbeaPyeLl4Wk-WyRGMhWTAnRWgQJT5WCswRyNUIXQVmzB9PVsfyVnXAvGrAK0aWYtWrBWm1yhEBNy_fd317WfewyxbFwwWPf1sd2HUnClUyG0lD16dUD32wZtuetcA913-b-D-AEl22LF |
| CitedBy_id | crossref_primary_10_1016_j_biomaterials_2020_119907 crossref_primary_10_1016_j_cct_2021_106400 crossref_primary_10_1177_09622802211037067 crossref_primary_10_1002_14651858_CD011044_pub3 crossref_primary_10_1002_sim_8788 crossref_primary_10_1016_j_jclinepi_2021_03_018 crossref_primary_10_1002_sim_9690 crossref_primary_10_1002_sim_9648 crossref_primary_10_1080_10543406_2022_2141769 crossref_primary_10_1053_j_gastro_2025_07_021 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1097/MPA.0000000000001234 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1536-4828 |
| ExternalDocumentID | 30629024 |
| Genre | Journal Article |
| GroupedDBID | --- .-D .XZ .Z2 0R~ 123 4Q1 4Q2 4Q3 53G 5RE 5VS 8L- AAAAV AAHPQ AAIQE AAJCS AAMTA AARTV AASCR AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADGGA ADHPY AE3 AE6 AEBDS AENEX AFDTB AFEXH AFUWQ AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK C45 CS3 DIWNM DU5 E.X EBS EEVPB EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ JK3 JK8 K8S KD2 KMI L-C N9A NPM O9- OAG OAH ODA ODMTH OHYEH OJAPA OL1 OLG OLV OLW OLZ OPUJH OVD OVDNE OWW OWY OXXIT P2P RLZ S4R S4S TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W YFH ZFV 7X8 ABPXF ABXYN ABZZY ACBKD ADKSD AFBFQ AFNMH AHQVU AOQMC |
| ID | FETCH-LOGICAL-c407t-8a95fa7acf6acdce6ec27829d2bac629dac641019200d7aed35ddedadd9c67e22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000456715300026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1536-4828 |
| IngestDate | Sun Nov 09 14:11:30 EST 2025 Wed Feb 19 02:34:41 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c407t-8a95fa7acf6acdce6ec27829d2bac629dac641019200d7aed35ddedadd9c67e22 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 30629024 |
| PQID | 2179322944 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2179322944 pubmed_primary_30629024 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-01 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Pancreas |
| PublicationTitleAlternate | Pancreas |
| PublicationYear | 2019 |
| SSID | ssj0017359 |
| Score | 2.3199522 |
| Snippet | The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 275 |
| Title | The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30629024 https://www.proquest.com/docview/2179322944 |
| Volume | 48 |
| WOSCitedRecordID | wos000456715300026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA_qRHzx-2N-EcHXsDXL0uZJNnH4YEsRhb2N7HqBobZzm-Kf76Xt2JMg2If0JQ0l3P3ud7nLHWM3Osu83QtE4NAKZRGF8SVcwUVRQOCIXSgvCj-GSRINhyatD9zmdVrlEhNLoM4K8GfkLeklSUqj1O30Q_iuUT66WrfQWGeNDlEZr5jhcBVFCDtlszRSai0UuRbLq3MmbMVprypdWD8E4Op3klkam8Huf39zj-3UNJP3KrnYZ2uYH7CtuA6kH7InEg_eJ5xzE19GZP7K-z7HEZAXjid2LFILvnz3N77xSc5jXFh_9WgCPKVZJdEE3iPMIlM4oyWLd3vEXgb3z3cPom6vIIC8uIWIrOk6G1pw2kIGqBEk8QWTybEFTW8aVeApYLudhRazTpewMCNANKBDlPKYbeRFjqeMazXW1o01EDlSRmKkwFpaIJDosONck10vd2tE4utjEjbH4nM-Wu1Xk51UWz6aVnU2RuTNSEMc4uwPX5-zbaIypsqnvmANR8qLl2wTvhaT-eyqlAsakzT-AdCYwvU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Benefit-Risk+Balance+of+Nab-Paclitaxel+in+Metastatic+Pancreatic+Adenocarcinoma&rft.jtitle=Pancreas&rft.au=P%C3%A9ron%2C+Julien&rft.au=Giai%2C+Joris&rft.au=Maucort-Boulch%2C+Delphine&rft.au=Buyse%2C+Marc&rft.date=2019-02-01&rft.issn=1536-4828&rft.eissn=1536-4828&rft.volume=48&rft.issue=2&rft.spage=275&rft_id=info:doi/10.1097%2FMPA.0000000000001234&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-4828&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-4828&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-4828&client=summon |